Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID‐19 intensive care unit patients

Aims Nadroparin is administered to COVID‐19 intensive care unit (ICU) patients as thromboprophylaxis. Despite existing population pharmacokinetic (PK) models for nadroparin in literature, the population PK of nadroparin in COVID‐19 ICU patients is unknown. Moreover, optimal dosing regimens achieving anti‐Xa target levels (0.3–0.7 IU/mL) are unknown. Therefore, a population PK analysis was conducted to investigate different dosing regimens of nadroparin in COVID‐19 ICU patients. Methods Anti‐Xa levels (n = 280) from COVID‐19 ICU patients (n = 65) receiving twice daily (BID) 5700 IU of subcutaneous nadroparin were collected to perform a population PK analysis with NONMEM v7.4.1. Using Monte Carlo simulations (n = 1000), predefined dosing regimens were evaluated. Results A 1‐compartment model with an absorption compartment adequately described the measured anti‐Xa levels with interindividual variability estimated for clearance (CL). Inflammation parameters C‐reactive protein, D‐dimer and estimated glomerular filtration rate based on the Chronic Kidney Disease Epidemiology Collaboration equation allowed to explain the interindividual variability of CL. Moreover, CL was decreased in patients receiving corticosteroids (22.5%) and vasopressors (25.1%). Monte Carlo simulations demonstrated that 5700 IU BID was the most optimal dosing regimen of the simulated regimens for achieving prespecified steady‐state t = 4 h anti‐Xa levels with 56.7% on target (0.3–0.7 IU/mL). Conclusion In our study, clearance of nadroparin is associated with an increase in inflammation parameters, use of corticosteroids, vasopression and renal clearance in critically ill patients. Furthermore, of the simulated regimens, targeted anti‐Xa levels were most adequately achieved with a dosing regimen of 5700 IU BID. Future studies are needed to elucidate the underlying mechanisms of found covariate relationships.

[1]  I. Ilyas,et al.  Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies , 2022, Acta Pharmacologica Sinica.

[2]  P. Pickkers,et al.  Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients , 2021, British journal of clinical pharmacology.

[3]  Christopher M. Horvat,et al.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 , 2021, The New England journal of medicine.

[4]  S. Susen,et al.  Pharmacokinetics of enoxaparin in COVID-19 critically ill patients , 2021, Thrombosis Research.

[5]  W. F. Abdo,et al.  Late augmented renal clearance in patients with COVID-19 in the intensive care unit. A prospective observational study , 2021, Journal of Critical Care.

[6]  D. Roccatello,et al.  Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection , 2020, Thrombosis Research.

[7]  D. Ramaekers,et al.  Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study , 2020, Thrombosis Research.

[8]  C. Hackeng,et al.  Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit , 2020, Thrombosis Research.

[9]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[10]  A. Gasbarrini,et al.  Incidence of deep vein thrombosis among non‐ICU patients hospitalized for COVID‐19 despite pharmacological thromboprophylaxis , 2020, Journal of Thrombosis and Haemostasis.

[11]  T. Tomasa-Irriguible,et al.  Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance! , 2020, Critical Care.

[12]  D. Leaf,et al.  COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection , 2020, Blood.

[13]  J. Douketis,et al.  Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[14]  Mickaël Ohana,et al.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[15]  J. Fichet,et al.  Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA network open.

[16]  D. Gommers,et al.  Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis , 2020, Thrombosis Research.

[17]  G. Grasselli,et al.  Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis , 2020, Journal of Thrombosis and Haemostasis.

[18]  D. Gommers,et al.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.

[19]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[20]  P. Suk,et al.  Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors , 2019, Pharmacology.

[21]  Robert J Bauer,et al.  NONMEM Tutorial Part II: Estimation Methods and Advanced Examples , 2019, CPT: pharmacometrics & systems pharmacology.

[22]  Robert J Bauer,et al.  NONMEM Tutorial Part I: Description of Commands and Options, With Simple Examples of Population Analysis , 2019, CPT: pharmacometrics & systems pharmacology.

[23]  M. Hutmacher,et al.  Covariate selection in pharmacometric analyses: a review of methods , 2015, British journal of clinical pharmacology.

[24]  Michael N Neely,et al.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. , 2014, The Lancet. Infectious diseases.

[25]  V. Ramanan,et al.  Estimation of renal function in the intensive care unit: the covert concepts brought to light , 2014, Journal of Intensive Care.

[26]  E. P. Dongen,et al.  Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint , 2014, European Journal of Clinical Pharmacology.

[27]  R J Keizer,et al.  Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose , 2013, CPT: pharmacometrics & systems pharmacology.

[28]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development , 2012, CPT: pharmacometrics & systems pharmacology.

[29]  T. Baglin,et al.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[30]  J. Roberts,et al.  Implications of augmented renal clearance in critically ill patients , 2011, Nature Reviews Nephrology.

[31]  Mats O. Karlsson,et al.  Likelihood based approaches to handling data below the quantification limit using NONMEM VI , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[32]  M O Karlsson,et al.  Diagnosing Model Diagnostics , 2007, Clinical pharmacology and therapeutics.

[33]  E. Niclas Jonsson,et al.  Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..

[34]  M. Levi,et al.  Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors , 2002, The Lancet.

[35]  P L Bonate,et al.  A Brief Introduction to Monte Carlo Simulation , 2001, Clinical Pharmacokinetics.

[36]  S. Laporte,et al.  Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[37]  Roger W. Jelliffe,et al.  Individualizing Drug Dosage Regimens: Roles of Population Pharmacokinetic and Dynamic Models, Bayesian Fitting, and Adaptive Control , 1993, Therapeutic drug monitoring.